1. Kannel WB, Schwartz MJ, McNamara PM (1969) Blood pressure and risk of
coronary heart disease: the Framingham study. Dis Chest 56: 43–52.
2. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, et al. (1990) Blood pressure,
stroke, and coronary heart disease. Part 1, Prolonged differences in blood
pressure: prospective observational studies corrected for the regression dilution
bias. Lancet 335: 765–774.
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002) Age-specific
relevance of usual blood pressure to vascular mortality: a meta-analysis of
individual data for one million adults in 61 prospective studies. Lancet 360:
1903–1913.
4. Petersen S PV, Rayner M, Leal J, Luengo-Fernandez R, Gray A (2005)
European cardiovascular disease statistics 2005 edition. European cardiovascular
disease statistics, British Heart Foundation.
5. Ward R (1995) Familial aggregation and genetic epidemiology of blood pressure.
In: Laragh JH, Brenner BM, eds. Hypertension : pathophysiology, diagnosis,
and management. 2nd ed. New York: Raven Press.
6. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, et al. (1997) A
clinical trial of the effects of dietary patterns on blood pressure. DASH
Collaborative Research Group. N Engl J Med 336: 1117–1124.
7. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, et al. (2001) Long-term
weight loss and changes in blood pressure: results of the Trials of Hypertension
Prevention, phase II. Ann Intern Med 134: 1–11.
8. Lifton RP, Gharavi AG, Geller DS (2001) Molecular mechanisms of human
hypertension. Cell 104: 545–556.
9. Xu B, English JM, Wilsbacher JL, Stippec S, Goldsmith EJ, et al. (2000) WNK1,
a novel mammalian serine/threonine protein kinase lacking the catalytic lysine
in subdomain II. J Biol Chem 275: 16795–16801.
10. Verissimo F, Jordan P (2001) WNK kinases, a novel protein kinase subfamily in
multi-cellular organisms. Oncogene 20: 5562–5569.
11. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, et
al. (2001) Human hypertension caused by mutations in WNK kinases. Science
293: 1107–1112.
12. Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J, et al. (2003)
Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to
identify potential targets for therapeutic intervention. Proc Natl Acad Sci U S A
100: 14109–14114.
13. Naray-Fejes-Toth A, Snyder PM, Fejes-Toth G (2004) The kidney-specific
WNK1 isoform is induced by aldosterone and stimulates epithelial sodium
channel-mediated Na+ transport. Proc Natl Acad Sci U S A 101: 17434–17439.
14. Cope G, Murthy M, Golbang AP, Hamad A, Liu CH, et al. (2006) WNK1
affects surface expression of the ROMK potassium channel independent of
WNK4. J Am Soc Nephrol 17: 1867–1874.
15. Golbang AP, Cope G, Hamad A, Murthy M, Liu CH, et al. (2006) Regulation of
the Expression of the Na/Cl cotransporter (NCCT) by WNK4 and WNK1:
evidence that accelerated dynamin-dependent endocytosis is not involved.
Am J Physiol Renal Physiol.
16. Lazrak A, Liu Z, Huang CL (2006) Antagonistic regulation of ROMK by long
and kidney-specific WNK1 isoforms. Proc Natl Acad Sci U S A 103: 1615–1620.
17. Subramanya AR, Yang CL, Zhu X, Ellison DH (2006) Dominant-negative
regulation of WNK1 by its kidney-specific kinase-defective isoform. Am J Physiol
Renal Physiol 290: F619–624.
18. Shekarabi M, Girard N, Riviere JB, Dion P, Houle M, et al. (2008) Mutations in
the nervous system–specific HSN2 exon of WNK1 cause hereditary sensory
neuropathy type II. J Clin Invest 118: 2496–2505.
19. Delaloy C, Lu J, Houot AM, Disse-Nicodeme S, Gasc JM, et al. (2003) Multiple
promoters in the WNK1 gene: one controls expression of a kidney-specific
kinase-defective isoform. Mol Cell Biol 23: 9208–9221.
20. Newhouse SJ, Wallace C, Dobson R, Mein C, Pembroke J, et al. (2005)
Haplotypes of the WNK1 gene associate with blood pressure variation in a
severely hypertensive population from the British Genetics of Hypertension
study. Hum Mol Genet 14: 1805–1814.
21. Tobin MD, Raleigh SM, Newhouse S, Braund P, Bodycote C, et al. (2005)
Association of WNK1 gene polymorphisms and haplotypes with ambulatory
blood pressure in the general population. Circulation 112: 3423–3429.
22. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E (2005) WNK1 kinase
polymorphism and blood pressure response to a thiazide diuretic. Hypertension
46: 758–765.
23. Gibbs RA, Belmont JW, Hardenbol P, Willis TD, Yu F, et al. (2003) The
International HapMap Project. Nature 426: 789–796.
24. Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, et al. (2003)
Genome-wide mapping of human loci for essential hypertension. Lancet 361:
2118–2123.
25. Clarke R, Emberson JR, Parish S, Palmer A, Shipley M, et al. (2007) Cholesterol
fractions and apolipoproteins as risk factors for heart disease mortality in older
men. Arch Intern Med 167: 1373–1378.
26. Strazzullo P, Barbato A, Galletti F, Barba G, Siani A, et al. (2006) Abnormalities
of renal sodium handling in the metabolic syndrome. Results of the Olivetti
Heart Study. J Hypertens 24: 1633–1639.
27. Galletti F, Barbato A, Versiero M, Iacone R, Russo O, et al. (2007) Circulating
leptin levels predict the development of metabolic syndrome in middle-aged
men: an 8-year follow-up study. J Hypertens 25: 1671–1677.
28. de Bakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ, et al. (2005) Efficiency
and power in genetic association studies. Nat Genet 37: 1217–1223.
29. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
30. Ihaka R, Gentleman R (1996) R: A Language for Data Analysis and Graphics.
Journal of Computational and Graphical Statistics 5: 219–314.
31. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score
tests for association between traits and haplotypes when linkage phase is
ambiguous. Am J Hum Genet 70: 425–434.
32. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR (2005) Adjusting for treatment
effects in studies of quantitative traits: antihypertensive therapy and systolic
blood pressure. Stat Med 24: 2911–2935.
33. Cui JS, Hopper JL, Harrap SB (2003) Antihypertensive treatments obscure
familial contributions to blood pressure variation. Hypertension 41: 207–210.
34. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring
inconsistency in meta-analyses. Bmj 327: 557–560.
35. Fu Y, Subramanya A, Rozansky D, Cohen DM (2006) WNK kinases influence
TRPV4 channel function and localization. Am J Physiol Renal Physiol.
36. Tobin MD, Timpson NJ, Wain LV, Ring S, Jones LR, et al. (2008) Common
Variation in the WNK1 Gene and Blood Pressure in Childhood. The Avon
Longitudinal Study of Parents and Children. Hypertension.
37. Gordon RD (1986) Syndrome of hypertension and hyperkalemia with normal
glomerular filtration rate. Hypertension 8: 93–102.
38. Delaloy C, Hadchouel J, Imbert-Teboul M, Clemessy M, Houot AM, et al.
(2006) Cardiovascular expression of the mouse WNK1 gene during development
and adulthood revealed by a BAC reporter assay. Am J Pathol 169: 105–118.
39. O’Reilly M, Marshall E, Speirs HJ, Brown RW (2003) WNK1, a gene within a
novel blood pressure control pathway, tissue-specifically generates radically
different isoforms with and without a kinase domain. J Am Soc Nephrol 14:
2447–2456.
40. Achard JM, Warnock DG, Disse-Nicodeme S, Fiquet-Kempf B, Corvol P, et al.
(2003) Familial hyperkalemic hypertension: phenotypic analysis in a large family
with the WNK1 deletion mutation. Am J Med 114: 495–498.
41. Modiano G, Bombieri C, Ciminelli BM, Belpinati F, Giorgi S, et al. (2005) A
large-scale study of the random variability of a coding sequence: a study on the
CFTR gene. Eur J Hum Genet 13: 184–192.
42. Zhu X, Fejerman L, Luke A, Adeyemo A, Cooper RS (2005) Haplotypes
produced from rare variants in the promoter and coding regions of
angiotensinogen contribute to variation in angiotensinogen levels. Hum Mol
Genet 14: 639–643.
43. Ji W, Foo JN, O’Roak BJ, Zhao H, Larson MG, et al. (2008) Rare independent
mutations in renal salt handling genes contribute to blood pressure variation.
Nat Genet 40: 592–599.
44. Tobin MD, Tomaszewski M, Braund PS, Hajat C, Raleigh SM, et al. (2008)
Common variants in genes underlying monogenic hypertension and hypotension
and blood pressure in the general population. Hypertension 51: 1658–1664.
45. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, et al. (2004)
Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science
305: 869–872.
46. Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, et al. (2006) Multiple
rare variants in NPC1L1 associated with reduced sterol absorption and plasma
low-density lipoprotein levels. Proc Natl Acad Sci U S A 103: 1810–1815.
47. Ahituv N, Kavaslar N, Schackwitz W, Ustaszewska A, Martin J, et al. (2007)
Medical sequencing at the extremes of human body mass. Am J Hum Genet 80:
779–791.
48. Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, et al. (2009) Rare
loss-of-function mutations in ANGPTL family members contribute to plasma
triglyceride levels in humans. J Clin Invest 119: 70–79.
49. Luna A, Nicodemus KK (2007) snp.plotter: an R-based SNP/haplotype
association and linkage disequilibrium plotting package. Bioinformatics 23:
774–776.